SCM
IRD

Stonepine Capital Management’s Opus Genetics IRD Stock Holding History

Stonepine Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$313K Buy
+68,688
New +$238K 0.13% 64

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Stonepine Capital Management's IRD Position: Q1 2026 in Review

Stonepine Capital Management opened a new position in Opus Genetics (IRD) in Q1 2026: 68,688 shares worth $313K. The stake represents 0.13% of the portfolio and ranks #64 among its holdings.

79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Stonepine Capital Management held 68,688 shares of Opus Genetics worth $313K as of Q1 2026.
  • Opus Genetics was a new Stonepine Capital Management position in Q1 2026.
  • Opus Genetics made up 0.13% of Stonepine Capital Management's portfolio in Q1 2026, its #64 holding.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.